Francisco Anguita-Santos

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Jesús Rodríguez‐Baño, Jerónimo Pachón, Jordi Carratalà et al. · Clinical Microbiology and Infection · 2020 · 127 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Effects of rituximab in connective tissue disorders related interstitial lung disease

Gemma Lepri, Jérôme Avouac, Paolo Airó et al. · PubMed · 2016 · 68 citations

Medicine, Clinical Sciences, Pharmacotherapy +14

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study

Ismael Francisco Aomar Millán, Juan Salvatierra, Úrsula Torres-Parejo et al. · Internal and Emergency Medicine · 2021 · 51 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +16

Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications

María Núñez‐Núñez, Inmaculada Casas-Hidalgo, Ricardo García-Fumero et al. · European Journal of Hospital Pharmacy · 2018 · 17 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +17

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation

Ismael Francisco Aomar-Millán, Juan Salvatierra, Úrsula Torres-Parejo et al. · Medicina Clínica (English Edition) · 2021 · 11 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +14